Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
For Phase 1, the following exclusions apply:
For Phase 2, the following exclusions apply:
Clovis Oncology Clinical Trial Navigation, phone: 1-855-262-3040 or email
This study will look at how safe, effective and tolerable the oral PARP inhibitor Rucaparib is when used in combination with other anticancer agents in patients with a solid tumor.
This is an open-label study, with two treatment arms.
Participants will be assigned to one of two groups:
Participants in both groups will be followed for up to two years.